CD30/TNFRSF8 Antibody (Ber-H2), Novus Biologicals™

CD30/TNFRSF8

Monoclonal

0.2mg/mL

Flow Cytometry 5 - 10 ul/million cells in 0.1ml, Immunohistochemistry, Immunohistochemistry-Paraffin 1:50 - 1:100, Immunofluorescence 1:50 - 1:100

P28908, P28908

TNFRSF8

Co cell line established from a patient with Hodgkin s disease of T-cell lineage

0.1 mL

Apoptosis, Cell Cycle and Replication, Embryonic Stem Cell Markers, Immunology, Stem Cell Markers

943

Human

Supernatant

Flow Cytometry, Immunohistochemistry, Immunohistochemistry (Paraffin), Immunofluorescence

Ber-H2

Unconjugated

No buffer with 0.05% Sodium Azide

CD30, CD30 antigen, CD30KI-1, CD30L receptor, cytokine receptor CD30, D1S166EKi-1, Ki-1 antigen, Lymphocyte activation antigen CD30, tumor necrosis factor receptor superfamily member 8, tumor necrosis factor receptor superfamily, member 8

Mouse

Tissue culture supernatant

RUO

Primary

Recognizes a single chain glycoprotein of 105/120kDa, identified as CD30/Ki-1. Its epitope is located between aa112-412. CD30 is synthesized as a 90kDa precursor, which is processed in the Golgi complex into a membrane-bound phosphorylated mature 105/120kDa glycoprotein. In Hodgkin s disease, CD30/Ki-1 antigen is expressed by mononuclear-Hodgkin and multinucleated Reed-Sternberg cells. It is also expressed by the tumor cells of a majority of anaplastic large cell lymphomas as well as by a varying proportion of activated T and B cells. This MAb distinguishes large cell lymphomas derived from activated lymphoid cells from histiocytic malignancies and lymphomas derived from resting and precursor lymphoid cells or from anaplastic carcinomas. About one third of the Ki-1 positive lymphomas lack the leukocyte common antigen (CD45).

Store at 4C.

IgG1 κ